Please check your internet connection and try again.
# Pantoprazole (Pantop DS)
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. "DS" typically refers to the double-strength (40 mg) formulation.
## Primary Indications
* Treatment/healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis/treatment of NSAID-induced ulcers.
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose is 40 mg PO twice daily. Doses up to 240 mg/day have been utilized based on patient response; titrate to clinical effect.
* **IV Administration:** 40 mg daily or twice daily via 15-minute infusion; switch to oral as soon as possible.
## Pediatric Dosing
* **Ages ≥ 5 years (GERD):**
* 15 kg to < 40 kg: 20 mg PO daily.
* ≥ 40 kg: 40 mg PO daily.
* **Duration:** Typically limited to 8 weeks; safety/efficacy beyond this is not well-established in pediatrics.
## Dose Adjustments
* **Hepatic Impairment:** No specific adjustment necessary for mild-to-moderate impairment. For severe impairment, consider monitoring closely; clinical guidelines may recommend dose reduction depending on the specific formulation.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (long-term, high-dose use).
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts).
* **CYP2C19:** Generally less interaction potential than omeprazole, but use caution with clopidogrel if patient is a CYP2C19 poor metabolizer (though clinical significance remains debated).
* **Methotrexate:** May increase methotrexate levels, especially in combination with high-dose therapy.
## Monitoring
* Monitor for worsening of symptoms or signs of infection (e.g., *C. difficile*).
* For long-term therapy (> 1 year): Monitor magnesium levels, B12 status, and bone density if risk factors are present.
* Symptom assessment to determine the necessity of ongoing therapy.
## Clinical Pearls
* **Timing:** Administer 30–60 minutes before a meal for optimal absorption.
* **Formulation:** Delayed-release tablets must be swallowed whole; do not crush or chew.
* **Deprescribing:** Assess the need for PPI therapy regularly. Avoid abrupt discontinuation after chronic use to prevent rebound acid hypersecretion; consider a slow taper.
* **IV vs Oral:** Oral bioavailability is high; IV dosing should be reserved for patients unable to tolerate oral intake.
***
*Disclaimer: This information is for educational purposes only. Clinical practice and dosing protocols may vary by institution. Always verify current prescribing information, package inserts, and local clinical guidelines before administration.*
